Tech Company Financing Transactions

TriGemX Bio Funding Round

TriGemX Bio closed a $236 million Series D funding round on 2/27/2022. Investors included Mubadala, The Column Group and Alexandria Venture Investments.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

430 East 29th St. 8th Floor
New York, NY 10016
USA

Phone

Undisclosed

Website

www.trigemxbio.com

Email Address

[email protected]

Overview

We are leveraging unique insights into neural signaling pathways and developing innovative medicines for the treatment of migraine. Our late-stage pipeline focuses on delivering an effective, easy to use, first-in-class medication. The company leverages unique scientific insights into neural signaling pathways to target specific peripheral sensory structures.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jeff Goater

        

Chief Financial Officer

Aninda Katragadda

        

Chief Medical Officer

Brett Lauring

        

Browse more venture capital transactions:

Prev: 2/27/2022: Parse Biosciences venture capital transaction
Next: 2/27/2022: Evolve Vacation Rental Network venture capital transaction

Share this article

Where The Data Comes From

We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary